A review of avelumab in locally advanced and metastatic bladder cancer
Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287218823485 |
| _version_ | 1818879554145484800 |
|---|---|
| author | Arpit Rao Manish R. Patel |
| author_facet | Arpit Rao Manish R. Patel |
| author_sort | Arpit Rao |
| collection | DOAJ |
| description | Urothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer. |
| first_indexed | 2024-12-19T14:31:55Z |
| format | Article |
| id | doaj.art-a54bc26e3c2b4872934c2195ea499e02 |
| institution | Directory Open Access Journal |
| issn | 1756-2880 |
| language | English |
| last_indexed | 2024-12-19T14:31:55Z |
| publishDate | 2019-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Urology |
| spelling | doaj.art-a54bc26e3c2b4872934c2195ea499e022022-12-21T20:17:26ZengSAGE PublishingTherapeutic Advances in Urology1756-28802019-01-011110.1177/1756287218823485A review of avelumab in locally advanced and metastatic bladder cancerArpit RaoManish R. PatelUrothelial carcinoma remains a devastating disease with a poor prognosis. Though immune therapy with Bacillus Calmette–Guérin (BCG) has been used for localized bladder cancer for years, only immune-checkpoint blockade with antiprogrammed cell-death 1 (anti-PD-1) and antiprogrammed cell-death ligand 1 (anti-PD-L1) inhibitors have demonstrated improvement in survival of patients with metastatic disease. Anti-PD-L1 antibody, avelumab, was recently given United States Food and Drug Administration (FDA) accelerated approval for the treatment of recurrent/metastatic urothelial carcinoma after failure of first-line chemotherapy, marking the fifth immune checkpoint inhibitor to be given FDA approval for the treatment of metastatic urothelial cancer. The following manuscript will review avelumab, its pharmacology, and the clinical experience that has led to its approval, as well as future plans for clinical development of avelumab for the treatment or urothelial cancer.https://doi.org/10.1177/1756287218823485 |
| spellingShingle | Arpit Rao Manish R. Patel A review of avelumab in locally advanced and metastatic bladder cancer Therapeutic Advances in Urology |
| title | A review of avelumab in locally advanced and metastatic bladder cancer |
| title_full | A review of avelumab in locally advanced and metastatic bladder cancer |
| title_fullStr | A review of avelumab in locally advanced and metastatic bladder cancer |
| title_full_unstemmed | A review of avelumab in locally advanced and metastatic bladder cancer |
| title_short | A review of avelumab in locally advanced and metastatic bladder cancer |
| title_sort | review of avelumab in locally advanced and metastatic bladder cancer |
| url | https://doi.org/10.1177/1756287218823485 |
| work_keys_str_mv | AT arpitrao areviewofavelumabinlocallyadvancedandmetastaticbladdercancer AT manishrpatel areviewofavelumabinlocallyadvancedandmetastaticbladdercancer AT arpitrao reviewofavelumabinlocallyadvancedandmetastaticbladdercancer AT manishrpatel reviewofavelumabinlocallyadvancedandmetastaticbladdercancer |